Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats HER2-overexpressing breast cancer. Sold as Trazimera. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Trastuzumab-Qyyp (sold as Trazimera), first approved Mar 11, 2019, with 0 new uses approved and 1 published complete response letter.
First approved: Mar 11, 2019
Applications: 1
New uses approved: 0
Complete response letters: 1
Medicare spending, 2025: $38.4M
First approved in the EU: Aug 28, 2000
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
HerceptinDrugs with a new indication and a new dosage for the treatment of unresectable advanced or recurrent HER2-positive colon or rectal cancer that has… · Chugai Pharmaceutical Co., Ltd. · Mar 28, 2022 · Review report
HerceptinDrugs with a new indication and a new dosage for the treatment of unresectable advanced or recurrent HER2-positive salivary gland tumors. · Chugai Pharmaceutical Co., Ltd. · Nov 25, 2021
HerceptinDrugs with a new dosage for the treatment of breast cancer with HER2 overexpression. · Chugai Pharmaceutical Co., Ltd. · Jun 14, 2013
HerceptinDrugs with a new additional indication and a new dosage for the treatment of breast cancer with HER2 overexpression. · Chugai Pharmaceutical Co., Ltd. · Nov 25, 2011
HerceptinDrugs with a new additional indication and a new dosage for the treatment of unresectable advanced or recurrent gastric cancer with HER2 overexpression. · Chugai Pharmaceutical Co., Ltd. · Mar 10, 2011
Clinical Trials
10 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
